
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros Corp has demonstrated financial resilience with a rise in other income to $2.1 million due to increased interest income from its substantial cash reserves, highlighting a strengthened balance sheet. The approval of a $100 million open-ended share repurchase program indicates management's confidence in the company's strategic trajectory and overall financial health. Notably, significant clinical trial results show a complete response in 61% of pivotal study patients and 100-day survival rates between 73% to 74%, underscoring the potential effectiveness of narsoplimab in treating serious health conditions.
Bears say
Omeros Corporation has shown a decline in research and development expenses, which indicates a reduction in investment towards advancing clinical trials, particularly the wind-down of several key studies. The discontinuation of the RIVER Phase 2a trial, the Human Abuse Potential study, and the CORAL Phase 2b trial may signal challenges in the clinical progress of its drug candidates. Such a decrease in R&D spending, coupled with potential setbacks in drug development, may adversely affect the company's growth prospects and investor confidence.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares